moderate-to-high - Refractive vision correction is an elective, out-of-pocket procedure highly sensitive to consumer discretionary spending and confidence. During economic downturns, patients defer elective surgeries, directly impacting procedure volumes. The company's exposure to China and Asia-Pacific markets creates additional sensitivity to regional economic conditions, currency fluctuations, and consumer spending patterns in those geographies. However, the premium positioning and younger demographic target (typically 21-45 years old with stable employment) provides some insulation versus mass-market healthcare products.

Rising interest rates create moderate headwinds through two channels: (1) higher rates reduce consumer willingness to finance elective procedures or divert discretionary spending toward debt service, and (2) growth-stage medical device companies with negative cash flow face higher valuation compression as discount rates increase and investors rotate toward profitable businesses. The company's current negative operating margins and cash consumption make it more vulnerable to rate-driven multiple contraction than profitable peers. However, minimal debt (0.11 D/E ratio) limits direct financing cost impact.

growth - The company historically attracted growth investors based on the large addressable market for refractive correction (estimated 2+ billion myopes globally), innovative product platform, and international expansion opportunity. However, recent operational deterioration and negative profitability have likely shifted the investor base toward distressed/turnaround investors or those betting on a return to growth trajectory. The negative margins and cash burn eliminate dividend and value investors. High volatility (evidenced by 43% six-month decline) attracts momentum and tactical traders but deters long-term institutional holders seeking stability.